23 FEB 2024 | EU | Samsung Bioepis Presented Study Results for ustekinumab SB17, Biosimilar to Janssen’s Stelara®, at ECCO On 23 February 2024, Samsung Bioepis presented two new...
Pearce IP BioBlast w/e 23 Feb 2024
read more
New Head of Legal and Special Counsel join Pearce IP from Big Law
Pearce IP is delighted to welcome Executive Lawyer and Head of Legal Helen Macpherson, and Special Counsel Chantal Savage to its legal team. Helen and Chantal join Pearce IP...
It’s a dog’s life
Zoetis Services LLC opposed two Australian patent applications (one standard and one innovation patent application) in the name of Boehringer Ingelheim Vetmedica GmbH. The applications claim a method of treating heart failure due to asymptomatic myxomatous mitral valve disease (MMVD) in a patient (including a dog) by administering pimobendan (also known as Vetmedin®).
Pearce IP BioBlast w/e 16 Feb 2024
19 JAN 2024 | AU | March a Bumper Month for Biopharma at the Pharmaceutical Benefits Assessment Committee (PBAC) in Australia According to the Pharmaceutical Benefits Assessment...
Pearce IP Welcomes Executive and Head of Trade Marks, Kim Evans
Pearce IP is delighted to welcome Executive Lawyer & Trade Mark Attorney Kim Evans to the team. Kim leads the Pearce IP trade mark team, and joins Pearce IP from Allens...
Pearce IP BioBlast w/e 09 Feb 2024
09 FEB 2024 | AU | Biocon Biologics Enter a Five-year Exclusive Partnership with Sandoz in Australia for Trastuzumab and Bevacizumab Biosimilars On 9 February 2024, Biocon...
Pearce IP BioBlast w/e 02 Feb 2024
2 FEB 2024 | EU | US | Regeneron’s linvoseltamab MAA Filing Accepted by EMA; BLA Submitted to FDA for Multiple Myeloma Regeneron announced that its marketing authorisation...
European Geographical Indications in New Zealand
On 24 January 2024 New Zealand introduced a new IP Bill for Geographical Indications (GIs). The bill will amend NZ law to implement aspects of the Free Trade Agreement with the...
Pearce IP BioBlast w/e 26 Jan 2024
26 JAN 2024 | SG | AbbVie to Expand Biologics Manufacturing Facility in Singapore with US$223M Investment AbbVie announced it will invest US$233M in its biologics manufacturing...
Pearce IP BioBlast w/e 19 Jan 2024
19 JAN 2024 | US | Alvotech Provides Update on FDA Facility Inspection for AVT02 and AVT04 Alvotech announced that its facility in Iceland received a form 483 from the FDA with...
Interlocutory injunction Granted to Restrain Alleged Patent Infringement in New Zealand
The High Court of New Zealand is only rarely called on to determine applications for interlocutory injunctions in proceedings alleging patent infringement. The decision in this case was that, despite taking more than a
Pearce IP BioBlast w/e 12 Jan 2024
12 JAN 2024 | EU | Celltrion Wins European Bids for Yuflyma® (adalimumab) and Remsima® (infliximab) Korea Biomedical Review reported that Celltrion has won bids to supply...
Pearce IP BioBlast w/e 05 Jan 2024
05 JAN 2024 | AU | Celltrion’s Remsima SC®, Biobetter to Remsima®, Biosimilar to Janssen’s Remicade® (infliximab), Sales Jump 48% The Korea Biomedical Review has reported that...
If you play with fire, you might get burnt – Full Court confirms Trafalgar warning letters on invalid innovation patent breach ACL but are not unjustified threats
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP’s Founder is Australasian Lawyer’s 2023 Most Influential Lawyer – Changemaker
We are delighted to announce that Pearce IP’s founder and CEO Naomi Pearce has been honoured by Australasian Lawyers as one of Australia’s Most Influential Lawyers in 2023....
Erroneous understanding of Australian law not an error qualifying for an extension of time
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP & Founder Naomi Pearce Ranked in Chambers and Partners APAC Guide 2024
We are delighted to announce that Pearce IP is ranked in the Chambers and Partners Guide for 2024 in the category of Intellectual Property. Pearce IP’s Founder and CEO Naomi...
BioBlast w/e 15 Dec 23
15 DEC 2023 | KR | Approval Alert: LG Chem’s Xelenka® Biosimilar to AbbVie’s Humira® (adalimumab) Approved in Korea Korea Biomed reported that LG Chem’s Xelenka®, biosimilar to...
BioBlast w/e 08 Dec 23
08 DEC 2023 | US | FDA Approves First Cell-Based Gene Therapies Casgevy® and Lyfgenia® to Treat Sickle Cell Disease The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and...
Pearce IP’s Jacinta Flattery-O’Brien Amongst Australia’s Patent Elite – Top 18 Global Leaders Named by IAM
Pearce IP is proud to announce that Jacinta Flattery-O’Brien PhD has again been named as one of Australia’s patent elite in the 2024 edition of IAM Global Leaders. Jacinta is...
BioBlast w/e 01 Dec 23
01 DEC 2023 | US | Celltrion Files BLA for Interchangeable Prolia® (Denosumab) Biosimilar with the FDA The Korea Biomedical Review reported that Celltrion has submitted an...
LAA under water – the great cost of commercialising before filing a patent application
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 24 Nov 23
24 NOV 2023 | Celltrion Applies For EU Approval of CT-P42, Biosimilar to Regeneron’s Eylea® (aflibercept) Celltrion revealed in a corporate filing with the Repository of Korea’s...
“Essence or Core” of an invention – Full Court adds non-statutory element to sufficiency in first appellate decision post-RTB
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.